Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 3/20 | 0.58 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.58 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.58 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA9 | Q16790 | 3/20 | 0.45 |
| ▸ | PYGB | P11216 | 6/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| B-D-Galactose SCHEMBL10050866 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| B-D-Galactose SCHEMBL2441804 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| B-D-Galactose SCHEMBL13220216 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| B-D-Galactose SCHEMBL18649521 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| B-D-Galactose SCHEMBL8527882 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| B-D-Galactose SCHEMBL23758905 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| B-D-Galactose SCHEMBL17112445 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| B-D-Galactose SCHEMBL79549 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| B-D-Galactose SCHEMBL21123450 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| B-D-Galactose SCHEMBL9820102 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11801305-B2 | Glycotargeting therapeutics | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) (CH) | 2023-10-31 | — | — | US | disclosed |
| US-11793882-B2 | Glycotargeting therapeutics | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) (CH) | 2023-10-24 | — | — | US | disclosed |
| US-11654188-B2 | Glycotargeting therapeutics | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2023-05-23 | — | — | US | disclosed |
| US-20180200753-A1 | Methods of Forming MLD Films Using Polyols With Long Carbon Backbones | ULTRATECH, INC. | 2018-07-19 | — | — | US | disclosed |
| US-20170296636-A9 | GLYCOTARGETING THERAPEUTICS | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) (CH) | 2017-10-19 | — | — | US | disclosed |
| US-20170159105-A1 | Enzyme Assays on a Droplet Actuator | ADVANCED LIQUID LOGIC, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170159105-A1 | Enzyme Assays on a Droplet Actuator | ADVANCED LIQUID LOGIC, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-9574220-B2 | Enzyme assays on a droplet actuator | ADVANCED LIQUID LOGIC, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9574220-B2 | Enzyme assays on a droplet actuator | ADVANCED LIQUID LOGIC, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20170007708-A1 | GLYCOTARGETING THERAPEUTICS | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) (CH) | 2017-01-12 | — | — | US | disclosed |
| US-20110150984-A1 | METHODS OF INCREASING THE BIOAVAILABILITY AND/OR CELLULAR UPDATE OF DRUGS | HET NEDERLANDS KANKER INSTITUUT (NL) | 2011-06-23 | — | — | US | disclosed |
| US-7915227-B2 | Pharmaceutical formulations employing short-chain sphingolipids and their use | HET NEDERLANDS KANKER INSTITUUT (NL) | 2011-03-29 | — | — | US | disclosed |
| US-20100240144-A1 | IMPROVED SERRS SUBSTRATE | E2V BIOSENSORS LIMITED (GB) | 2010-09-23 | — | — | US | disclosed |
| US-20090081634-A1 | FLUORESCENT AND SACCHARIDIC SUBSTRATES, THEIR PROCESS OF PREPARATION AND THEIR USE | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2009-03-26 | — | — | US | disclosed |
| US-20080299044-A1 | Saccharide Fluorescent Substrates, Preparation Method and Uses Thereof | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2008-12-04 | — | — | US | disclosed |
| WO-2007110614-A2 | IMPROVED SERRS SUBSTRATE | E2V BIOSENSORS LIMITED (GB) | 2007-10-04 | — | — | WO | disclosed |
| US-20070161580-A1 | Anti-Tumor Compounds With Angeloyl Groups | PACIFIC ARROW LIMITED (CN) | 2007-07-12 | — | — | US | disclosed |
| US-20070161580-A1 | Anti-Tumor Compounds With Angeloyl Groups | PACIFIC ARROW LIMITED (CN) | 2007-07-12 | — | — | US | disclosed |
| US-20070082855-A1 | Pharmaceutical formulations employing short-chain sphingolipids and their use | HET NEDERLANDS KANKER INSTITUUT (NL) | 2007-04-12 | — | — | US | disclosed |
| WO-2007010145-A2 | SACCHARIDE FLUORESCENT SUBSTRATES, PREPARATION METHOD AND USES THEREOF | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11801305-B2 | Glycotargeting therapeutics | LGALS3BP, LGALS1, CD47 | LGALS3 4/4885LGALS1 2/4885LGALS9 18/4885 |
| US-11793882-B2 | Glycotargeting therapeutics | CD74, LGALS1, LY96 | LGALS3 4/4885LGALS1 2/4885LGALS9 29/4885 |
| US-20170007708-A1 | GLYCOTARGETING THERAPEUTICS | CD74, LGALS1, LY96 | LGALS3 4/4885LGALS1 2/4885LGALS9 29/4885 |
| US-11654188-B2 | Glycotargeting therapeutics | B3GAT3, UGGT1, MRGPRX1 | LGALS3 30/4885LGALS1 15/4885LGALS9 83/4885 |
| US-20070161580-A1 | Anti-Tumor Compounds With Angeloyl Groups | SPG11, ST14, MCL1 | LGALS3 100/4885LGALS1 607/4885LGALS9 352/4885 |
| US-20110150984-A1 | METHODS OF INCREASING THE BIOAVAILABILITY AND/OR CELLULAR UPDATE OF DRUGS | NPC1L1, SGMS2, SGMS1 | LGALS3 808/4885LGALS1 675/4885LGALS9 1189/4885 |
| US-20080299044-A1 | Saccharide Fluorescent Substrates, Preparation Method and Uses Thereof | FUCA1, MPI, ENGASE | LGALS3 476/4885LGALS1 183/4885LGALS9 609/4885 |
| US-20070082855-A1 | Pharmaceutical formulations employing short-chain sphingolipids and their use | SGMS1, SGMS2, CERT1 | LGALS3 1320/4885LGALS1 1631/4885LGALS9 1163/4885 |
| US-20170296636-A9 | GLYCOTARGETING THERAPEUTICS | B3GAT3, UGGT1, MRGPRX1 | LGALS3 30/4885LGALS1 15/4885LGALS9 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.